Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer · Vertex Pharmaceuticals Inc (VRTX)

Ian Smith

A named executive officer of Vertex Pharmaceuticals in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,451,840

Salary $75,192Stock awards $0

FY2018: $4,626,134

8th of 8 named executive officers at Vertex Pharmaceuticals by FY2019 total.

8 named officers on file for Vertex Pharmaceuticals, FY2019

Ian Smith’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • VRTX’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vertex Pharmaceuticals’s whole pay program stands against its peers

  • Vertex Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2020 (DEF 14A).

Free

Get Ian Smith’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ian Smith compensation by year

Vertex Pharmaceuticals Summary Compensation Table · all 4 fiscal years held
In US dollars, as Vertex Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$750,000$848,077$850,000$75,192
Bonus$0$0$0$0
Stock awards$3,150,148$2,625,016$2,625,244$0
Option awards$1,305,144$1,110,263$1,136,785$0
Non-equity incentive$562,500$1,339,770$0$0
Pension and deferred compensation$0$0$0$0
All other$12,885$13,110$14,105$1,376,648
Total$5,780,677$5,936,236$4,626,134$1,451,840

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 28, 2020, accession 0001308179-20-000229, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-20-000229. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2020.

$5.8M
$5.9M
$4.6M
$1.5M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,350$1,715,099—
RSU8,649$1,433,226—
RSU8,437$1,398,095—
RSU5,767$955,650—
RSU4,219$699,130—
PSU4,219$699,130—
RSU1,917$317,666—
Option10,776—$91.05
Option15,898—$155.57
Option17,475—$86.52
Option6,375—$131.89
Option4,250—$109.14

Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Vertex Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Jeffrey LeidenExecutive Chairman (CEO and President through March 31, 2020)$18,789,985
Stuart ArbuckleEVP & Chief Commercial Officer$6,859,533
Reshma KewalramaniCEO and President (EVP & Chief Medical Officer through March 31, 2020)$6,816,936
Amit SachdevEVP & Chief Patient Officer$6,197,053
Michael PariniEVP & Chief Administrative, Legal and Business Development Officer$6,039,497
Charles WagnerEVP & Chief Financial Officer$3,487,213
Paul SilvaSVP & Corporate Controller (Interim CFO for a portion of 2019)$3,197,857
Ian Smith · this pageFormer EVP & Chief Operating Officer and Former Interim Chief Financial Officer$1,451,840

The full Vertex Pharmaceuticals compensation record

free company brief

This page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vertex Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ian Smith's compensation dossier · One-time report. No refunds.